Table 3.
Trends in Baseline Demographic and Clinical Characteristics of Patients with Surgically Managed Pancreatic Adenocarcinoma, Surveillance, Epidemiology, and End Results–Medicare, 1991–2005
| Total (n = 2,461) |
1991–1996 (n = 568) |
1997–2000 (n = 539) |
2001–2002 (n = 500) |
2003–2005 (n = 854) |
|
|---|---|---|---|---|---|
| Demographics | |||||
| Age at PAC diagnosis, y, mean ± SEM* | 73.2 ± 0.1 | 72.1 ± 0.2 | 72.9 ± 0.2 | 73.5 ± 0.3 | 74.0 ± 0.2 |
| Women,* n (%) | 1321 (53.7) | 290 (51.1) | 276 (51.2) | 275 (55.0) | 480 (56.2) |
| White, n (%) | 2056 (83.5) | 464 (81.7) | 443 (82.2) | 431 (86.2) | 718 (84.1) |
| Married, n (%) | 1516 (61.6) | 344 (60.6) | 344 (63.8) | 289 (57.8) | 539 (63.1) |
| Urban, n (%) | 2304 (93.6) | 523 (92.1) | 505 (93.7) | 477 (95.4) | 799 (93.6) |
| Elixhauser comorbidities,* n (%) | |||||
| No comorbidities | 839 (34.1) | 281 (49.5) | 206 (38.2) | 142 (28.4) | 210 (24.6) |
| 1 comorbidity | 662 (26.9) | 151 (26.6) | 140 (26.0) | 132 (26.4) | 239 (28.0) |
| 2 comorbidities | 460 (18.7) | 77 (13.6) | 100 (18.6) | 100 (20.0) | 183 (21.4) |
| ≥3 comorbidities | 500 (20.3) | 59 (10.4) | 93 (17.3) | 126 (25.2) | 222 (26.0) |
| Time from diagnosis of PAC to operation, d, mean ± SEM* | 13.8 ± 0.4 | 9.1 ± 0.7 | 12.3 ± 0.8 | 13.7 ± 0.9 | 18.0 ± 0.8 |
| Pathology, n (%) | |||||
| SEER historic stage* | |||||
| Localized | 446 (18.1) | 111 (19.5) | 108 (20.0) | 92 (18.4) | 135 (15.8) |
| Regional | 2015 (81.9) | 457 (80.5) | 431 (80.0) | 408 (81.6) | 719 (84.2) |
| Grade | |||||
| Well-differentiated | 252 (10.2) | 65 (11.4) | 50 (9.3) | 54 (10.8) | 83 (9.7) |
| Moderately differentiated | 1160 (47.1) | 271 (47.7) | 228 (42.3) | 239 (47.8) | 422 (49.4) |
| Poorly differentiated | 788 (32.0) | 157 (27.6) | 197 (36.5) | 168 (33.6) | 266 (31.1) |
| Undifferentiated | 30 (1.2) | <11 (<1.9) | <11 (<2.0) | <11 (<2.2) | <11 (<1.3) |
| Unknown | 231 (9.4) | <11 (<1.9) | <11 (<2.0) | <11 (<2.2) | <11 (<1.3) |
| Lymph node metastasis,* n (%) | 1333 (54.2) | 287 (50.5) | 268 (49.7) | 263 (52.6) | 515 (60.3) |
*
Significant at p < 0.05 by either ANOVA test or the linear-by-linear association test of trend.
PAC, pancreatic adenocarcinoma; SEER, Surveillance, Epidemiology, and End Results cancer registry.